Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Medical Devices

Minutes From Negotiation Meeting on MDUFA III Reauthorization, February 10, 2012

FDA – Industry MDUFA III Reauthorization Meeting
February 10, 2012, 1:00 pm – 1:45 pm
Teleconference

Purpose
To discuss MDUFA III reauthorization.

Participants

FDA
Malcolm BertoniOffice of the Commissioner (OC)
Nathan Brown           Office of Chief Counsel (OCC)
Kate CookCenter for Biologics Evaluation and Research (CBER)
Christy ForemanCenter for Devices and Radiological Health (CDRH)
Elizabeth HillebrennerCDRH
Toby LoweCDRH
Don St. PierreCDRH
Francisco VicentyCDRH
Nicole WolanskiCDRH
Barbara ZimmermanCDRH
Industry
Jen BowmanAmerican Clinical Laboratories Association
Brian ConnellMedical Imaging Technology Alliance
Mark LeaheyMedical Device Manufacturers Association
James RugerQuest Diagnostics (representing ACLA)
Janet TrunzoAdvanced Medical Technology Association

Meeting Start Time:  1:00pm

Industry presented a proposal for the MDUFA III fee structure.  Given that the actual PMA fee for fiscal year 2012 is lower then expected due to the offset, Industry proposed setting the PMA fee at a level that avoids a steep increase in relation to FY 2012 actual fees.  Industry proposed increasing 510(k) fees from 1.84% to 2.0% of PMA fees.  Industry’s proposed registration fee assumes the elimination of exemptions for facility registrations.

Industry noted this proposal includes collections that exceed estimated expenditures in fiscal years 2013 and 2014, which balance out in the remaining three years during which expenditures exceed collections; during these years, carryover balances are used to make up the year-by-year difference. 

FDA indicated that the general approach proposed by Industry is reasonable.  FDA will evaluate the proposal in detail and provide feedback promptly. 

The parties discussed the Agency’s lack of authority to spend the MDUFA II fee over-collections (due to lack of appropriation), despite lowering the fees in FY 2012 to offset the over-collections.  The parties agreed that this outcome was inconsistent with Congressional intent and created a problem that continues into FY 2012.  One goal of the MDUFA III fee structure is to minimize over-collections that result in a high offset balance.  Due to uncertainty regarding how elimination of exemptions may impact the number of facility registrations, FDA suggested allowing the fees to be adjusted annually to better estimate the targeted fee collections for each year.  

Next Meeting

The next meeting will take place February 14, 2012.

Meeting End Time:  1:45 pm

Page Last Updated: 07/16/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.